Epi Biotech에피바이오텍

Epi Biotech, a small KONEX-listed hair-loss drug developer, has risen sharply recently but has no reported revenue or earnings in the data provided.

Epi Biotech is developing EPI-001, an autologous dermal papilla cell therapy for hair loss, which received clinical trial approval in Korea in December 2023. The data shows a ₩45.0B market cap and a share price of ₩19,510, up 56.3% over three months and 25.4% over one year. Financial statements, trailing earnings and valuation multiples are not available in the data provided.

What stands out

• The share price is ₩19,510, close to its 52-week high of ₩21,000, after gains of 21.2% over one month and 56.3% over three months.
• Annual financial data and trailing twelve-month figures are not included in the data, so revenue, profit and cash position cannot be assessed from it.
• Valuation ratios such as P/E, P/B and EV/EBITDA are not available, while listed peers like Samsung Biologics and Celltrion trade at much larger market caps.
• Recent filings are mostly routine: a shareholders' meeting notice and record-date setting in October 2026, IR events in September and October, and the annual report for December 2025 filed in March 2026.
• Retail investors held the net buying over the last 20 days, while institutions were net sellers; foreign ownership is 0%.

What to watch

• The shareholders' meeting called in October 2026 and its agenda, once the details are available in the filings.
• Any clinical trial progress updates for EPI-001, which the data does not describe beyond the December 2023 approval.
• The first full set of audited annual financials showing revenue and losses, since none appear in the data provided.